Harrington Prize for Innovation in Medicine has been awarded to Owen N. Witte, MD, Distinguished University Professor and President's Chair in Developmental Immunology, David Geffen School of Medicine ...

These drugs target tyrosine kinase proteins like the BCR-ABL protein to help stop CML cells from growing and replicating. Examples of TKIs that doctors may prescribe to help treat CML include ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...

At the time, the BCR-ABL tyrosine kinase was the best-credentialed tyrosine kinase target in oncology. A couple of years earlier, I had advised Nick that CML, driven by BCR-ABL kinase activity ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

Already-listed Enliven Therapeutics, which develops small-molecule kinase inhibitors for cancer ... of Enliven’s two lead candidates, BCR-ABL inhibitor ELVN-001 for chronic myeloid leukaemia ...

IFN-α2 (in most centers today pegylated IFN-α2 [Peg-IFN-α2]) induces major or complete molecular remissions in a subset of JAK2V617-positive patients with essential thrombocythemia (ET) and ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Future Microbiol. 2009;4(2):223-240.